See Our Latest Insights
on the impacts of COVID-19.

$483 Million

Immunomedics, Inc.

Follow-on Offering

Lead Left Bookrunner, April 2020

Immunomedics, Inc. (“Immunomedics” or the “Company”) is developing and commercializing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. The Company received U.S. FDA accelerated approval for Trodelvy (sacituzumab govitecan) on April 22, 2020 for the treatment of adult patients with metastatic triple-negative breast cancer (“mTNBC”) who have received at least two prior therapies for metastatic disease.

More Like This

May 2020
$40 Million

Follow-on Offering

Lead Left Bookrunner

View Details
May 2020
$175 Million

Follow-on Offering

Lead Left Bookrunner

View Details
May 2020
$862 Million

Follow-on Offering

Bookrunner

View Details